Thomas P Parks

Title: Thomas P. Parks: Innovator in Immunomodulation

Introduction: Thomas P. Parks, based in Ridgefield, Connecticut, is a distinguished inventor known for his contributions to the field of immunology. With a patent to his name, his work has significant implications for treating various immune disorders.

Latest Patents: Thomas P. Parks holds a patent for "4-substituted beta-carbolines and analogs thereof." This invention focuses on compounds that inhibit Ca²⁺ influx and interleukin-2 (IL-2) production. These 4-substituted beta-carbolines and their analogs possess the potential to selectively modulate immune responses, making them valuable in preventing and treating autoimmune diseases, inflammatory diseases, organ transplant rejection, and other disorders linked to IL-2 mediated responses.

Career Highlights: Thomas is associated with Boehringer Ingelheim Pharmaceuticals, Inc., a leading global pharmaceutical company. His work there demonstrates a commitment to developing innovative therapeutic solutions that enhance patient care and address significant health challenges.

Collaborations: Throughout his career, Thomas has collaborated with esteemed colleagues, including Clara K. Miao and Ian F. Potocki. These partnerships contribute to a dynamic research environment, fostering innovation and the advancement of therapeutic modalities.

Conclusion: Thomas P. Parks is a noteworthy inventor whose work in the field of immunology showcases the potential of 4-substituted beta-carbolines as therapeutic agents. His contributions to Boehringer Ingelheim Pharmaceuticals, Inc. and collaborations with fellow innovators underscore the importance of teamwork in advancing medical science and improving health outcomes.